Cargando…
Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer
Though palbociclib, a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor has been approved for treating breast cancer, two major clinical challenges remain: (i) Triple-negative breast cancer (TNBC) appears to be more resistant to palbociclib, and (ii) Palbociclib-induced senescence-associated secre...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522654/ https://www.ncbi.nlm.nih.gov/pubmed/37752122 http://dx.doi.org/10.1038/s41420-023-01658-w |
_version_ | 1785110398109745152 |
---|---|
author | Wang, Xianzhe Shi, Wei Wang, Xumei Lu, Jin-Jian He, Ping Zhang, Hongjie Chen, Xiuping |
author_facet | Wang, Xianzhe Shi, Wei Wang, Xumei Lu, Jin-Jian He, Ping Zhang, Hongjie Chen, Xiuping |
author_sort | Wang, Xianzhe |
collection | PubMed |
description | Though palbociclib, a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor has been approved for treating breast cancer, two major clinical challenges remain: (i) Triple-negative breast cancer (TNBC) appears to be more resistant to palbociclib, and (ii) Palbociclib-induced senescence-associated secretory phenotype (SASP) has a pro-tumorigenic function. Here we report that combining palbociclib with the STAT3 inhibitor nifuroxazide uncouples SASP production from senescence-associated cell cycle exit. Moreover, we identified nifuroxazide as a CDK2 inhibitor that synergistically promotes palbociclib-induced growth arrest and senescence in TNBC cells. In vitro, the combination of nifuroxazide with palbociclib further inhibited the TNBC cell proliferation and enhanced palbociclib-induced cell cycle arrest and senescence. The modulation of palbociclib-induced SASP by nifuroxazide was associated with the reduction of phosphorylated-STAT3. Nifuroxazide also blocks SASP-dependent cancer cell migration. Furthermore, thermal shift assay and molecular docking of nifuroxazide with STAT3 and CDK2 revealed that it binds to their active sites and acts as a potent dual inhibitor. In vivo, the combination of nifuroxazide with palbociclib suppressed 4T1 tumor growth and lung metastasis. Our data suggest that nifuroxazide enhances the anticancer effects of palbociclib in TNBC by uncoupling SASP production from senescence-associated cell cycle exit and inhibiting CDK2 to promote tumor senescence. [Image: see text] |
format | Online Article Text |
id | pubmed-10522654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-105226542023-09-28 Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer Wang, Xianzhe Shi, Wei Wang, Xumei Lu, Jin-Jian He, Ping Zhang, Hongjie Chen, Xiuping Cell Death Discov Article Though palbociclib, a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor has been approved for treating breast cancer, two major clinical challenges remain: (i) Triple-negative breast cancer (TNBC) appears to be more resistant to palbociclib, and (ii) Palbociclib-induced senescence-associated secretory phenotype (SASP) has a pro-tumorigenic function. Here we report that combining palbociclib with the STAT3 inhibitor nifuroxazide uncouples SASP production from senescence-associated cell cycle exit. Moreover, we identified nifuroxazide as a CDK2 inhibitor that synergistically promotes palbociclib-induced growth arrest and senescence in TNBC cells. In vitro, the combination of nifuroxazide with palbociclib further inhibited the TNBC cell proliferation and enhanced palbociclib-induced cell cycle arrest and senescence. The modulation of palbociclib-induced SASP by nifuroxazide was associated with the reduction of phosphorylated-STAT3. Nifuroxazide also blocks SASP-dependent cancer cell migration. Furthermore, thermal shift assay and molecular docking of nifuroxazide with STAT3 and CDK2 revealed that it binds to their active sites and acts as a potent dual inhibitor. In vivo, the combination of nifuroxazide with palbociclib suppressed 4T1 tumor growth and lung metastasis. Our data suggest that nifuroxazide enhances the anticancer effects of palbociclib in TNBC by uncoupling SASP production from senescence-associated cell cycle exit and inhibiting CDK2 to promote tumor senescence. [Image: see text] Nature Publishing Group UK 2023-09-26 /pmc/articles/PMC10522654/ /pubmed/37752122 http://dx.doi.org/10.1038/s41420-023-01658-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Wang, Xianzhe Shi, Wei Wang, Xumei Lu, Jin-Jian He, Ping Zhang, Hongjie Chen, Xiuping Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer |
title | Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer |
title_full | Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer |
title_fullStr | Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer |
title_full_unstemmed | Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer |
title_short | Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer |
title_sort | nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of stat3 and cdk2 in triple-negative breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522654/ https://www.ncbi.nlm.nih.gov/pubmed/37752122 http://dx.doi.org/10.1038/s41420-023-01658-w |
work_keys_str_mv | AT wangxianzhe nifuroxazidebooststheanticancerefficacyofpalbociclibinducedsenescencebydualinhibitionofstat3andcdk2intriplenegativebreastcancer AT shiwei nifuroxazidebooststheanticancerefficacyofpalbociclibinducedsenescencebydualinhibitionofstat3andcdk2intriplenegativebreastcancer AT wangxumei nifuroxazidebooststheanticancerefficacyofpalbociclibinducedsenescencebydualinhibitionofstat3andcdk2intriplenegativebreastcancer AT lujinjian nifuroxazidebooststheanticancerefficacyofpalbociclibinducedsenescencebydualinhibitionofstat3andcdk2intriplenegativebreastcancer AT heping nifuroxazidebooststheanticancerefficacyofpalbociclibinducedsenescencebydualinhibitionofstat3andcdk2intriplenegativebreastcancer AT zhanghongjie nifuroxazidebooststheanticancerefficacyofpalbociclibinducedsenescencebydualinhibitionofstat3andcdk2intriplenegativebreastcancer AT chenxiuping nifuroxazidebooststheanticancerefficacyofpalbociclibinducedsenescencebydualinhibitionofstat3andcdk2intriplenegativebreastcancer |